Contents:

1 Executive Summary 2 Methodology 3 List of Contents 3.1 List of Boxes 3.2 List of Tables 4 The Lymphomas 4.1 Introduction 4.1.1 Disease Definition 4.1.2 Etiology & Pathophysiology 4.2 Epidemiology 4.3 Current Treatment Strategies 4.3.1 Hodgkins Disease 4.3.2 Radiation Therapy 4.3.3 Chemotherapy 4.3.4 Transplantation 4.3.5 Treatment Option Overview 4.4 Non-Hodgkins Lymphoma 4.4.1 Radiation Therapy 4.4.2 Chemotherapy 4.4.3 Immunotherapy 4.4.4 Bone Marrow and Peripheral Blood Transplants 4.4.5 Watch and Wait 4.4.6 Treatment Option Overview 4.5 Prognosis 4.5.1 Hodgkins Disease 4.5.2 Non-Hodgkin 4.6 Progress in Current Treatment Strategies 4.6.1 Hodgkin 4.6.2 Non-Hodgkin 4.6.3 Rituxan 4.6.4 Bexxar 4.6.5 Zevalin 4.7 Key Therapeutic Strategies for Future Treatments 4.7.1 Therapy Type, Targets & Mechanisms 4.8 Competitive Landscape in Drug Development: The Late Stage Pipeline 4.9 Current Drug Development: The Early Stage Pipeline 5 The Leukemias 5.1 Introduction 5.1.1 Disease Definitions 5.1.2 Etiology & Pathophysiology 5.1.3 The Lymphoid Malignancies 5.1.4 The Myeloid Malignancies 5.2 Epidemiology 5.3 Prognosis 5.3.1 The Lymphoid Malignancies 5.3.2 The Myeloid Malignancies 5.4 Current Treatment Strategies 5.4.1 The Lymphoid Malignancies 5.4.2 The Myeloid Malignancies 5.5 Progress in Current Treatment Strategies 5.5.1 The Lymphoid Malignancies 5.5.2 The Myeloid Malignancies 5.6 Key Therapeutic Strategies for Future Therapies 5.6.1 Therapeutic Type, Targets & Mechanisms 5.7 Competitive Landscape in Drug Development: The Late Stage Pipeline 5.7.1 The Lymphoid Malignancies 5.7.2 The Myeloid Malignancies 5.8 Current Drug Development: The Early Stage Pipeline 5.8.1 The Myeloid Malignancies 5.8.2 The Lymphoid Malignancies 5.9 Disclaimer 5.9.1 Liability 5.9.2 Completeness 6 Appendix: Drugs Approved for the Treatment of Leukemia: a Historical Perspective 7 Drug Index 8 Company Index 3.1 List of Boxes 67H Box 1: Possible Complications of Treatment 68HBox 2: Updated REAL/WHO Classification for B-Cell Neoplasms 69HBox 3: Subclassification of Stage 70HBox 4: Updated REAL/WHO Classification for B-Cell Neoplasms 71HBox 5: Updated REAL/WHO Classification for T-Cell and Putative NK-Cell Neoplasms 72HBox 6: Staging Subclassification System 73HBox 7 Study Details 74HBox 8: Major Treatment Regimes 75HBox 9: CLL Staging System 76HBox 10: Quick Facts - Clofarabine 7HBox 11: Quick Facts - Alemtuzumab 78HBox 12: Quick Facts - Gemtuzumab 79HBox 13: Quick Facts - Imatinib 80HBox 14: Quick Facts - Rituximab 81HBox 15: Quick Facts - Genasense 82HBox 16: Quick Facts - Flavopiridol 83HBox 17: Quick Facts - Atra 84HBox 18: Quick Facts - Gvax 85HBox 19: Quick Facts - Zarnestra 86HBox 20: Quick Facts - BAY 43-9006 Box 21: Quick Facts - Ceplene Box 22: Quick Facts - Valspodar Box 23: Quick Facts - CEP-701 Box 24: Quick Facts - PKC412 Box 25: Quick Facts - SU5416 Box 26: Quick Facts - PTK787 Box 27: Quick Facts - Cloretazine Box 28: Company Statement on Progress Box 29: Quick Facts - Troxacitabine Box 30: Quick Facts - FK228 Box 31: Quick Facts - Decitabine Box 32: Quick Facts - VELCADE Box 33: Velcade Sales 2005 Box 34: Quick Facts - AG-858 Box 35: Quick Facts - Avastin Box 36: Quick Facts - OSI-461 Box 37: Quick Facts - Xcytrin Box 38: Quick Facts - AP23573 3.2 List of Tables Table 1: Drugs Used in the Treatment of Lymphoma Table 2 Summary of Strategies Enhancing Antibody Function Table 3 Cancer Immunotherapy Strategies Table 4: Protein Kinase Targets in Clinical Trials for Lymphoma Table 5: Near Term Progress Aldesleukin Table 6: Near Term Progress Arsenic trioxide Table 7: Near Term Progress BiovaxID Table 8: Near Term Progress Bortezomib Table 9: Near Term Progress Epratuzumab Table 10: Near Term Progress FavId Table 11: Near Term Progress MyVax Table 12: Near Term Progress Nelarabine Table 13: Near Term Progress Genasense Table 14: Near Term Progress Pixantrone Table 15: Near Term Progress Temsirolimus Table 16: Near Term Progress Zanolimumab Table 17: Near Term Progress Flavopiridol Table 18: Near Term Progress Bevacizumab Table 19: Near Term Progress CMC-544 Table 20: Near Term Progress Galiximab Table 21: Near Term Progress LY317615 Table 22: Near Term Progress SGN-40 Table 23: Near Term Progress Apolizumab Table 24: Near Term Progress SGN-30 Table 25: ALL Classification Table 26: Latest Approved Drugs for the Treatment of Leukemia Table 27: Kinase Inhibitors in Development for the Treatment of Leukemia Table 28: Near Term Progress Rituximab Table 29: Near Term Progress Oblimersen Table 30: Near Term Progress Alvocidib Table 31: Near Term Progress ATRA Table 32: Near term progress GVAX Table 33: Near tearm progress HuM195 Table 34: Near term progress Zarnestra Table 35: Near Term Progress Sorafenib Table 36: Near Term Progress Valspodar Table 37: Summary of Current Late Stage Pipeline Table 38: Near term progress CEP-701 Table 39: Near Term Progress PKC412 Table 40: Near Term Progress SU5416 Table 41: Near Term Progress PTK787 Table 42: Near Term Progress VNP40101M Table 43: Near Term Progress Troxacitabine Table 44: Near Term Progress Decitabine Table 45 Near Term Progress Bortezomib Table 46 Near Term Progress AG-858 Table 47: Near Term Progress Bevacizumab Table 48: Near Term Progress OSI-461 Table 49: Near Term Progress Xcytrin Table 50: Near Term Progress AP23573 Table 51: Summary of Current Early Stage Pipeline